

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

RS-127445 hydrochloride

MedChemExpress

®

Cat. No.:	HY-15419	
CAS No.:	199864-86-3	H ₂ N N
Molecular Formula:	C ₁₇ H ₁₇ CIFN ₃	N
Molecular Weight:	317.79	
Target:	5-HT Receptor	
Pathway:	GPCR/G Protein; Neuronal Signaling	
Storage:	4°C, sealed storage, away from moisture	ŕ
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	H-CI

SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (393.34 mM; Need ultrasonic) H ₂ O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)				
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	3.1467 mL	15.7337 mL	31.4673 mL
		5 mM	0.6293 mL	3.1467 mL	6.2935 mL
		10 mM	0.3147 mL	1.5734 mL	3.1467 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	 Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.87 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-8-CD in saline) 				
	Solubility: ≥ 2.5 mg/mL (7.87 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.87 mM); Clear solution				

Description	RS-127445 hydrochloride is a selective, high affinity, orally bioavailable 5-HT _{2B} receptor antagonist with a pK _i of 9.5. RS- 127445 hydrochloride shows 1000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites ^[1] .			
IC ₅₀ & Target	sPLA2 5.5 (pKi)	5-HT ₃ Receptor <6 (рКі)	5-HT ₅ Receptor <6 (рКі)	5-НТ ₆ Receptor <6 (рКі)
	5-HT _{2A} Receptor	5-HT _{2C} Receptor	5-HT _{2B} Receptor	

	6.3 (pKi)	6.4 (рКі)	9.5 (рКі)
In Vitro	RS-127445 is found to has nat as compared to numerous ot human recombinant 5-HT _{2B} i receptor is 9.5±0.1 (n=9). RS-1 human recombinant 5-HT _{2A} , 1B/D receptor in bovine cauda nM) evoked increases in intra 10.4±0.1). In cells expressing of inositol phosphates (pK _B =5 blocks 5-HT-evoked contract the rat jugular vein (pA ₂ =9.9± MCE has not independently c	nomolar affinity for the 5-HT _{2B} re- her receptor and ion channel bin receptors expressed in CHO-K1 cd 127445 is selective for the 5-HT _{2B} 5-HT _{2C} , 5-HT ₅ , 5-HT ₆ and 5-HT ₇ r ate, and a monoamine uptake sit icellular calcium concentrations human recombinant 5-HT _{2B} rece 9.5±0.1) and 5-HT-evoked increas ion of rat isolated stomach fundu $(0.3)^{[1]}$.	eceptor (pK _i =9.5±0.1) and 1,000 fold selectivity for this receptor ding sites. RS-127445 potently displaces [³ H]-5-HT from ells. The affinity (pK _i value) of RS-127445 for the 5-HT _{2B} receptor, having approximately 1000 fold lower affinity for the receptors, a 5-HT _{1A} receptor in rat brain membranes, a 5-HT e in rabbit platelets. RS-127445 potently blocks the 5-HT (10 in the HEK-293 cells expressing the 5-HT _{2B} receptor (pIC ₅₀ of eptors, RS-127445 potently antagonizes 5-HT-evoked formation ses in intracellular calcium (pIC ₁₀ =10.4±0.1). RS-127445 also us (pA _{2B} =9.5±1.1) and (±) α -methyl-5-HT-mediated relaxation of methods. They are for reference only.
In Vivo	In rats, the fraction of RS-127 Intraperitoneal administration accessible 5-HT _{2B} receptors f intravenous routes. Peak plas first time-point measured foll by the oral route of administr approximately 1.7 h. The bios approximately 14 and 62% of and 14% of the oral dose of R faecal output, reaching signif MCE has not independently c	445 that is bioavailable via the or on of RS-127445 (5 mg/kg) produc for at least 4 h.RS-127445 (5 mg/k sma concentrations are rapidly a lowing intravenous and intraperi ration. RS-127445 is cleared from availability of RS-127445, when a f that obtained by intravenous ac S-127445 (5 mg/kg) is bioavailab ficance at 10 and 30 mg/kg (n=6-1 onfirmed the accuracy of these r	ral or intraperitoneal routes is 14 and 60% respectively. Seed plasma concentrations predicted to fully saturate (ag) is administered to rats by oral, intraperitoneal and chieved with the highest concentrations being found at the tonael administration (0.08 h) and by 0.25 h following dosing plasma with an estimated terminal elimination half-life of dministered by the oral and intraperitoneal routes is liministration. Approximately 60% of an intraperitoneal dose $le^{[1]}$. RS-127445 (1-30 mg/kg), dose-dependently reduces L1). In blood and brain, >98% of RS-127445 is protein-bound ^[2] . nethods. They are for reference only.

ΡΡΟΤΟΓΟΙ	
Cell Assay ^[1]	HEK-293 cells expressing the human 5-HT _{2B} receptor are incubated with [³ H]-myoinositol (1.67 μCi/mL) in 162 cm ² flasks overnight at 37°C in an inositol free Ham's F12 medium containing 10% dialyzed foetal bovine serum. The cells are harvested, washed five times with phosphate buffered saline and resuspended in inositol free Ham's F12 media at density approximately 3×10 ⁶ cells/mL. RS-127445 (10 μM) is initially dissolved in 10% (v/v) DMSO with 90% inositol free Ham's F12 medium. Subsequent dilutions are made with inositol free Ham's F12 medium. 5-HT is dissolved in inositol free Ham's F12 medium containing 100 mM LiCl and 1 mM ascorbate. RS-127445, vehicle or other antagonists are pre-incubated with 240 of cell suspension at 37°C for 20 min. The reactions are initiated by addition of 5-HT. Sixty minutes later, the reactions are terminated by adding 50 μL of ice-cold 20% perchloric acid, chilled in an ice-water bath for 10 min and then neutralized w 160 μL of 1 N KOH. Each sample is diluted with 2 ml of 50 mM Tris-HCl, pH 7.4 at room temperature. The aqueous portion (2.2 mL) is transferred onto Dowex AG1X8 columns (1 ml, 1 : 1, w/v) which had been washed with 5 ml of distilled water. Th columns are then washed with 18 ml of distilled water and the inositol phosphates are eluted with 3 ml of 1 N HCl. The eluted radioactivity is determined by liquid scintillation spectroscopy using a Packard 1900CA analyzer ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^{[1][2]}	Rats ^[1] Male Sprague-Dawley rats (200 g) are used. To compare the plasma kinetics of RS-127445 following different routes of administration, 90 rats are distributed into three treatment groups of 30 rats each. A single dose of RS-127445 (5 mg/kg) dissolved (2.5 mg/mL) in ethanol:propylene glycol : water (10 : 50 : 40, v:v:v), is administered to each rat. At 0.08, 0.25, 0.5, 2, 4, 8 and 24 h after dosing, the rats are anaesthetized and blood samples are collected by cardiac puncture. Mice ^[2] Adult male C57BL/6J mice (25-30 g) are used. The effects of RS-127445 (1 nM-10 μM, single concentration per tissue, 15 mi contact time) or vehicle (5 or 50 μL DMSO) are expressed as the percentage change in amplitude compared with the mean amplitude of four pre-drug, post-EFS contractile responses. The results are analysed using a two-sample equal variance t-

test.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Mol Neurobiol. 2023 Sep 25.
- Authorea. September 19, 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bonhaus DW, et al. RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol. 1999 Jul;127(5):1075-82.

[2]. Bassil AK, et al. Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology. Br J Pharmacol. 2009 Sep;158(1):252-8

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA